Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-08-14 DOI:10.1080/14796678.2024.2388478
Muhammad Hamayal, Warda Shahid, Chaudhary Humayun Akhtar, Fnu Shekiba, Iqra Iftikhar, Muhammad Danyal Tahir, Muhammad Awwab, Saima Hussain, Saman Naeem, Momina Hafeez
{"title":"Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis.","authors":"Muhammad Hamayal, Warda Shahid, Chaudhary Humayun Akhtar, Fnu Shekiba, Iqra Iftikhar, Muhammad Danyal Tahir, Muhammad Awwab, Saima Hussain, Saman Naeem, Momina Hafeez","doi":"10.1080/14796678.2024.2388478","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Statin intolerance and myopathy is a major issue with prolonged use of statins myopathy. Bempedoic acid can be a good alternative for those intolerant to statins. This systematic review aims to observe incidence of major adverse cardiovascular events (MACE) and other adverse events, in high-risk statin intolerant patients receiving bempedoic acid.<b>Methods:</b> Literature search was conducted via Google Scholar, Science Direct and PubMed, after which screening, selection and data extraction of articles was done. Meta-analysis was performed on RevMan 5.4. Subgroup analysis was also conducted and heterogeneity was evaluated. Risk of bias was performed using ROB2 assessment scale. (CRD42024536827).<b>Results:</b> Only six randomized controlled trials were used in final analysis consisting of 17,844 patients. Treatment with bempedoic acid was associated with a reduced risk of MACE compared with placebo (RR 0.86; 95% CI [0.79, 0.94] <i>p</i> = 0.0005), with myocardial infarction significantly reduced. Incidence of adverse effects was increased with bempedoic acid (RR: 1.02; 95% [1.00, 1.03] <i>p</i> = 0.01) but no significant difference was observed. Incidence of myalgia was reduced in bempedoic group as well.<b>Conclusion:</b> Bempedoic acid is a safe and effective alternative to statins in high-risk patients intolerant to statins, decreasing the risk of MACE.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2388478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Statin intolerance and myopathy is a major issue with prolonged use of statins myopathy. Bempedoic acid can be a good alternative for those intolerant to statins. This systematic review aims to observe incidence of major adverse cardiovascular events (MACE) and other adverse events, in high-risk statin intolerant patients receiving bempedoic acid.Methods: Literature search was conducted via Google Scholar, Science Direct and PubMed, after which screening, selection and data extraction of articles was done. Meta-analysis was performed on RevMan 5.4. Subgroup analysis was also conducted and heterogeneity was evaluated. Risk of bias was performed using ROB2 assessment scale. (CRD42024536827).Results: Only six randomized controlled trials were used in final analysis consisting of 17,844 patients. Treatment with bempedoic acid was associated with a reduced risk of MACE compared with placebo (RR 0.86; 95% CI [0.79, 0.94] p = 0.0005), with myocardial infarction significantly reduced. Incidence of adverse effects was increased with bempedoic acid (RR: 1.02; 95% [1.00, 1.03] p = 0.01) but no significant difference was observed. Incidence of myalgia was reduced in bempedoic group as well.Conclusion: Bempedoic acid is a safe and effective alternative to statins in high-risk patients intolerant to statins, decreasing the risk of MACE.

不耐受他汀类药物的高危患者使用贝母皂苷酸导致心血管后果的风险:系统综述和荟萃分析。
目的:他汀类药物不耐受和肌病是长期使用他汀类药物肌病的一个主要问题。对于他汀类药物不耐受者来说,本鱼腥草酸是一种不错的替代品。本系统性综述旨在观察他汀类药物不耐受的高危患者接受双鱼藤酸治疗后主要心血管不良事件(MACE)和其他不良事件的发生率。研究方法通过 Google Scholar、Science Direct 和 PubMed 进行文献检索,然后对文章进行筛选和数据提取。使用 RevMan 5.4 进行元分析。同时还进行了分组分析和异质性评估。偏倚风险采用 ROB2 评估量表进行评估。(CRD42024536827)。结果:只有六项随机对照试验被用于最终分析,其中包括 17,844 名患者。与安慰剂相比,使用贝门冬氨酸可降低MACE风险(RR 0.86; 95% CI [0.79, 0.94] p = 0.0005),其中心肌梗死风险显著降低。贝门冬氨酸会增加不良反应的发生率(RR:1.02;95% [1.00,1.03] p = 0.01),但未观察到显著差异。贝美多克组的肌痛发生率也有所降低。结论对于不能耐受他汀类药物的高危患者来说,鱼腥草酸是一种安全有效的他汀类药物替代品,可降低 MACE 风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信